GlobalData

The hepatitis C market is set to experience a steady decline, falling from $21.7 billion in 2015 to $17.5

The company's report states that this deterioration in sales, which will occur across the nine m

The main market for direct-acting antivirals (DAAs) curing patients of hepatitis C in 2015 was the US, c

Mirco Junker, Ph.D., Healthcare Analyst for GlobalData, notes: "The introduction of multiple pan-genoty

Europe's contribution to global hepatitis C DAAs is actually projected to increase slightly, from 20% in 2

Junker continues: "France, Germany, and the UK, for example, benefited from low prevalence rates an